Safety concerns moved to the front late in the Food and Drug Administration's Sept. 14 public hearing on psychedelic medicines, as speakers raised known cardiac risks, the need for health screening before treatment, and sexual misconduct by providers, Fierce Biotech reported. One speaker, Susan Taymor Sagy, co-founder of the nonprofit Coalition for Psychedelic Safety and Education, told regulators that her 21-year-old, Shira, died following psychedelic use. Fierce did not report the cause or circumstances of the death, and MedicalDaily has not independently confirmed them.
The timing matters because the field may be nearing a decision point. Fierce Biotech described the FDA as moving toward a likely first approval of a psychedelic medicine, an assessment from industry reporting rather than an agency announcement. Compass Pathways is in the process of submitting a rolling application for its synthetic psilocybin drug. On the day of the hearing, Definium Therapeutics announced a third positive phase 3 result for its LSD tablet and said it has an FDA meeting set for the fourth quarter to discuss an application, according to Fierce Biotech's trial report.
For families of someone living with depression, anxiety, or post-traumatic stress disorder (PTSD), the question is shifting from whether these drugs might arrive to how safely they would be given. That includes who screens patients, who stays in the room, and what happens for people with heart conditions or those already taking antidepressants.
Warnings Raised at the Hearing
Kevin Sabet, head of the Foundation for Drug Policy Solutions and a former White House drug policy adviser, argued that psychedelics should earn approval "through science and trials, not politics or podcasters." He said many phase 3 trials have used relatively small samples despite targeting very large patient groups. He also cited methodological problems, including poor sampling, suppressed negative results, and sexual misconduct, an issue Fierce said came up several times during the hearing.
Sagy said she supports rigorous research but urged regulators to think beyond the clinic. "FDA approval will carry enormous cultural weight," she said, according to Fierce. Speakers who raised safety concerns stressed that screening a patient's health before treatment is critical, along with close supervision during dosing.
Other testimony focused on who should deliver care. Rajan Dunne, a psychiatrist at Sheppard Pratt, called for required oversight by a psychiatrist, while nurse practitioner Tina Braddock argued that nurses are already trained and ready to do the work. Jon Dalton, president of the Nevada Coalition for Psychedelic Medicines, warned that an FDA expectation for an on-call physician to reach a site within 15 minutes could shut out qualified clinics in rural Nevada and other Western states.
The Heart and Medication Cautions in FDA Guidance
The FDA's July 2026 guidance on psychedelic clinical studies helps explain why heart health is part of the debate. It says the serotonin 5-HT2B receptor has been linked to heart valve disease in humans. It recommends excluding people with existing valve disease or pulmonary hypertension from multiple-dose studies of drugs with this activity until the risk is better understood, and it calls for heart ultrasounds before and after treatment for such drugs if they are given long term.
The guidance also flags medication interactions. Taking SSRIs, SNRIs, or MAO inhibitors for three weeks or more may weaken a psychedelic's effects, while taking tricyclic antidepressants or lithium for that long may intensify them, creating a potential psychiatric safety concern. Shorter use of SSRIs, SNRIs, or MAO inhibitors may also intensify the effects. Combining MAO inhibitors with MDMA or other amphetamine-based psychedelics can cause a life-threatening spike in blood pressure.
Supervision is central to the FDA's approach. The agency expects two trained monitors for the full session and warns that participants "may remain in a vulnerable state for several hours or longer." If the lead monitor is not a physician, a licensed on-call physician should be able to reach the site within 15 minutes. These are nonbinding recommendations for clinical trials, not final rules for how an approved drug would be used.
The evidence has clear limits. Definium's latest results, from a 245-patient trial, are company-announced topline figures that the FDA has not yet reviewed. A personal account at a public hearing is an important warning, but it cannot show how often serious harms occur.
Since the Earlier Hearing Preview
MedicalDaily previously reported on the FDA's hearing topics and how the public can weigh in. That report focused on the process, while the testimony now shows which safety issues speakers pressed hardest. Written comments remain open until 11:59 p.m. ET on Oct. 5 on docket FDA-2026-N-7542, and electronic comments are posted publicly.
The FDA has not approved any psilocybin, LSD, or MDMA product to treat depression, anxiety, or PTSD, as MedicalDaily's coverage of Definium's anxiety trial also noted. People considering unregulated psychedelics or retreats should talk with a clinician first, especially if they have heart disease or high blood pressure or take antidepressants or lithium. No one should stop a prescribed medication without medical guidance.
Chest pain, a severe headache, extreme agitation, or confusion after any drug use needs urgent care through 911. People in emotional distress or having thoughts of self-harm can call or text the 988 Suicide & Crisis Lifeline. Cost and access remain unknown, since treatments such as Definium's involve a single eight-hour monitored session and no product has been approved for insurers to cover.
The FDA has not said when it will act on the hearing input. Readers should watch for any draft policy on training and supervision, Compass's completed application, and Definium's fourth-quarter FDA meeting. Until a product is approved, families should rely on supervised, evidence-based care rather than unregulated use.
Key Questions Answered
What safety concerns came up at the hearing? Speakers raised known cardiac risks, the need for health screening before treatment, and sexual misconduct by providers. One speaker told the FDA that her 21-year-old died following psychedelic use.
Has the FDA approved a psilocybin, LSD, or MDMA drug? No. The FDA has not approved any of these for depression, anxiety, or PTSD, and it has not announced a decision on pending products.
Why is heart health part of the discussion? FDA guidance says the 5-HT2B receptor has been linked to heart valve disease. It recommends excluding people with valve disease or pulmonary hypertension from multiple-dose studies of drugs with this activity.
Do antidepressants interact with psychedelics? The FDA says taking SSRIs, SNRIs, or MAO inhibitors for three weeks or more may weaken the effects, while tricyclics or lithium may intensify them. MAO inhibitors combined with MDMA can cause a dangerous blood pressure crisis.
Who should be in the room during a dosing session? In clinical trials, the FDA expects two trained monitors for the full session. If the lead monitor is not a physician, an on-call physician should be able to reach the site within 15 minutes.
How can the public comment? Submit comments to docket FDA-2026-N-7542 on Regulations.gov by 11:59 p.m. ET on Oct. 5. Leave out private medical details, since electronic comments are posted publicly.
Where can someone get help right now? Call or text 988 for emotional distress or thoughts of self-harm. Call 911 for a medical emergency such as chest pain or confusion.
